Synergistic Activity of the Src Family Kinase Inhibitor Dasatinib and Oxaliplatin in Colon Carcinoma Cells is Mediated by Oxidative Stress

Chemotherapeutic regimens for the treatment of colorectal cancer generally include oxaliplatin, although inherent and acquired resistance is common. One potential mediator of oxaliplatin sensitivity is the non-receptor protein tyrosine kinase, Src, the activity of which correlates with disease stage...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Kopetz, Scott, Lesslie, Donald P., Dallas, Nikolas A., Park, Serk I., Johnson, Marjorie, Parikh, Nila U., Kim, Michael P., Abbruzzese, James L., Ellis, Lee M., Chandra, Joya, Gallick, Gary E.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2009
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2709758/
https://ncbi.nlm.nih.gov/pubmed/19383922
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-08-2246
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak